版本:
中国

BRIEF-Catalyst Biosciences’ Factor IX recommended for orphan drug designation in Europe

May 31 Catalyst Biosciences Inc

* Catalyst Biosciences’ Factor IX recommended for orphan drug designation in europe

* Catalyst Biosciences -isu abxis, plans to initiate phase 1/2 proof-of-concept study of cb 2679d in individuals with severe hemophilia b in june in south korea Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐